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Post-Dilation of
Superficial Femoral
Artery Stents With Cryoplasty
Does the COBRA Trial Take a
Bite Out of Diabetic Restenosis?*
Anand Prasad, MD
San Antonio, Texas
Over the past decade there has been an explosion in the
number of tools available for the endovascular treatment of
lower extremity peripheral arterial disease (PAD). Seem-
ingly every few months, the interventionalist is confronted
with a new device that promises to deliver both immediate
angiographic improvement and long-term freedom from
restenosis. Despite the increasing availability of newer
angioplasty balloons, nitinol stents, drug-coated devices,
and atherectomy cutters, the ideal treatment for an individ-
ual patient is unclear and often not based on rigorously
vetted data. In contrast to the coronary circulation, this
clinical uncertainty is largely the result of a paucity of
randomized controlled trials to evaluate the utility of these
devices.
See page 1352
In this issue of the Journal, Banerjee et al. (1) present data
rom a prospective multicenter randomized controlled pilot
rial (COBRA [Cryoplasty or Conventional Balloon Post-
ilation of Nitinol Stents for Revascularization of Periph-
ral Vascular Segments]) to examine the benefit of cryo-
lasty in diabetic patients using the PolarCath peripheral
ilatation system (Boston Scientific, Natick, Massachusetts)
s an adjunctive treatment after nitinol stent placement in
he superficial femoral artery (SFA). Cryoplasty using this
ystem has been approved since 2004. The widespread
doption of this technology has been limited by mixed
linical data and a lack of fundamental understanding of
ryobiology in relation to PAD. In comparison to drug-
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Department of Medicine, Division of Cardiology, University of Texasw
Health Science Center at San Antonio, San Antonio, Texas. Dr. Prasad has reported
that he has no relationships relevant to the contents of this paper to disclose.luting balloons, for example, where the biology of pacli-
axel has been studied extensively, the mechanisms under-
ying vascular responses to cryoplasty have lagged behind the
linical implementation of this tool.
echanisms of action. Cryoplasty (using the PolarCath)
s hypothesized to have 2 pathways of action on peripheral
essels. First, there is the standard effect of plaque disrup-
ion and vessel dilation using low pressure inflation. This
icroprocessor-controlled dilation is suggested to induce
ess mechanical barotrauma than conventional angioplasty.
f course, while a “low and slow” inflation may prevent
rauma and dissection, it may also limit acute gain and result
n restenosis or reocclusion. Therefore, the second and more
nteresting aspect of this device is the delivery of liquid
itrous oxide into the balloon system. As the liquid changes
hase to a gas, the balloon inflates and the associated heat
ransfer results in supercooling of the balloon to 10°C. As
lready mentioned, the physiological impact of cooling on
he vascular architecture remains an active area of study.
owever, several mechanisms have consistently emerged in
ultiple studies—mostly performed using animal-derived
issue and cell preparations (2–5). The pathway of most
iological relevance is apoptosis of vascular smooth muscle
ells with relative sparing of the endothelial cells. This
rocess is hypothesized to limit the inflammatory and
eactive responses to injury that often follow angioplasty,
eading to restenosis. Some data would suggest that both the
ate and magnitude of cooling directly impact the depth of
reatment within the vessel wall as well as the relative
alance between necrosis and apoptosis (5). However, the
uration and magnitude of smooth muscle cell suppression
n humans undergoing cryoplasty remain poorly defined.
linical data for use of cryoplasty in humans. The
arious studies that have examined the clinical utility of
ryoplasty for PAD in humans are highlighted in Table 1
6–22). The majority of these studies have consisted of
onrandomized single-center experiences. Accordingly, the
atient population, methods, and outcomes have varied
onsiderably. In most studies, the acute angiographic suc-
ess rates have been excellent; however the long-term rates
n regard to patency or target lesion revascularization have
een inconsistent—comparable (or worse in some studies)
han conventional percutaneous transluminal balloon angio-
lasty (PTA). The handful of small randomized trials to
ate have also not demonstrated an overwhelming benefit of
ryoplasty over PTA. In all of these trials, cryoplasty was
ooked to as a primary endovascular treatment (with stent-
ng reserved for bail-out). Therefore, underlining these trials
re basic mechanical limitations of PTA that are shared by
ryoplasty, namely, vascular recoil and dissection. Placement
f nitinol stents solves the problems associated with acute
ecoil and dissection, but continues to invite the bane of
estenosis. Accordingly, the benefits of routine stenting over
TA alone have been decidedly mixed in the literature. It is
ith these limitations in mind that the COBRA trial makes
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October 9, 2012:1360–3 The COBRA Trial and Diabetic Restenosissense: use a stent to counter the acute mechanical limita-
tions of PTA, and use cryoplasty to address the smooth
muscle mediated restenosis process.
What did we learn from the COBRA trial? Banerjee et al.
(1) used the aforementioned framework to perform a pilot
study of SFA nitinol stenting followed by post-dilation with
cryoplasty versus conventional balloon PTA. Forty-five
patients were randomly allocated to each group, and
notably, despite the small sample size, the 2 groups were
fairly well matched in terms of comorbid conditions. The
investigators used binary restenosis as their primary
endpoint, defined by a 2.5-fold increase in peak systolic
velocity within the stented segment. Patients in the
cryoplasty arm had PolarCath treatment once the nitinol
stent was in place as the final post-dilation treatment or
after conventional post-dilation. The entire length of the
stent was treated with cryotherapy. The key finding of the
study was a significant difference in the 12-month binary
restenosis rates (55.8% in the PTA arm and 29.3% in the
cryoplasty arm, p  0.01). Furthermore, as a secondary
ndpoint, there was a sustained improvement at 12
onths in the ankle-brachial index in the cryoplasty
roup that was not seen in the conventional PTA arm.
Given the unique post-dilation cryotherapy strategy of
he COBRA trial, it is difficult to directly compare these
ata with previous studies in the literature. However, 2
andomized studies have examined cryoplasty specifically in
iabetics. Spiliopoulos et al. (6) performed a small single-
enter randomized trial of cryoplasty (n  24) versus
onventional PTA (n 26) involving diabetic patients with
utherford stage 3 to 6 symptoms for femoropopliteal
isease. In this particular study—as in all the prior random-
zed cryoplasty trials—stenting was used only for bail-out
26% usage in cryoplasty arm). A particular strength of this
rial was the use of invasive follow-up and an angiographi-
ally determined binary restenosis definition. Immediate
echnical success rates were relatively low: 58.0% in the
ryoplasty arm and 64.0% in the PTA arm (p  0.29). The
esearchers found that in-lesion angiographic binary reste-
osis was significantly higher with cryoplasty at follow-up as
ompared with PTA. On multivariable analyses, cryoplasty
as associated with increased TLR events and decreased
essel patency. Fossaceca et al. (21) also compared PTA to
ryoplasty in 48 diabetic patients with femoropopliteal
isease in a prospective randomized trial. Echoing the
eneral findings of the study by Spiliopoulos et al. (6), the
nvestigators found that cryoplasty resulted in both an
ntermediate (6 months) and a longer term (12 months)
ecrease in vessel patency as well as a lower rate of initial
echnical success. Furthermore, they noted more pain dur-
ng inflation with cryoplasty as compared with PTA—a
henomenon that is not universally commented on in other
rials.
Given the small sample sizes, it is difficult to draw
efinitive conclusions, but these data involving diabetic
atients would suggest that, at a minimum, cryoplasty as arimary strategy is not a better treatment than traditional
TA. The results, however, do add to the rationale for the
OBRA trial. Stenting often provides a better acute pro-
edural result than PTA alone, and can improve the
mmediate technical success in complex calcified and dif-
usely diseased vessels as seen in diabetic patients. With
echanical scaffolding in place, cryoplasty can then be
onsidered as an adjuvant therapy to deter restenosis.
imitations of the COBRA trial and future strategies for
estenosis prevention. The findings of the COBRA trial
hould be taken in the light of a preliminary study. As a
mall trial, there were several notable limitations. First, the
uthors chose to study only diabetic patients. Although the
urden, severity, and poor outcomes of PAD in diabetic
atients are well documented, inclusion of a more varied
atient population would have allowed for a larger study and
ore generalizability to the general PAD population. Sec-
nd, as an inherent limitation of a small pilot study, it is not
ossible to know if the strategy of post-dilation employed in
he study will lead to any true difference in clinical out-
omes. Interestingly, both groups had an improvement in
ean walking impairment scores even though the signifi-
ant improvement in binary restenosis and the ankle-
rachial index was confined to the cryoplasty arm. Third,
he lack of angiographic follow-up in all patients limits the
natomical analyses in regard to stent fracture, collateral
ormation, and progression of plaque. Last, we cannot
redict where the strategy outlined in the COBRA trial will
t in with the current and upcoming endovascular treat-
ents for PAD. With the concerns of stent fracture and
estenosis, many interventionalists have migrated away from
tenting. In this regard, the role of primary debulking before
dditional treatments will have to be evaluated, as will the
ole of biodegradable technologies. In addition, the relative
fficacy of cryoplasty versus drug-eluting balloons for post-
ilation of nitinol stents will need to be studied.
Widespread adoption of this technology will also be
elped by a better understanding of the vascular biology of
ryotherapy. What is clear is the need for further funding
nd interest in performing randomized controlled trials for
AD revascularization. In this regard, Banerjee et al. (1)
hould be commended for their novel approach to a chal-
enging problem.
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e of Study Key Findings/Comments
d controlled trial
or popliteal stenoses
Initial technical success was 35% for
cryoplasty versus 54% for PTA (p  0.02);
bail-out stent placement was 30% for
cryoplasty versus 39% for PTA (p  NS);
no significant difference in target lesion
patency at 9 months between the
2 groups
of cryoplasty for
ns
Immediate technical success in all patients;
primary patency was poor (55%) at
12 months
ter experience of cryoplasty
moropopliteal, and
Immediate success rate of 99%; dissection
rate of 12.2% (no bail-out stenting used);
frequent need for reintervention, 42% of
patients at 6 months and 53% at 2 years
d controlled trial (PTA vs. Overall complications similar in both arms;
rate of dissection 13.5% in cryoplasty arm
with 22% rate of stent placement;
cryoplasty group had patency rates similar
to (but numerically lower) PTA at 6, 12,
24, and 36 months
d trial (PTA vs. cryoplasty) in
femoropopliteal disease
Conventional PTA superior to cryoplasty in
terms of technical success rates and
vessel restenosis at 6 months and
12 months
y; TASC   TransAtlantic InterSociety Consensus; TLR  target lesion revascularization.Typ
omize
asty) f
erience
l lesio
gle-cen
liac, fe
esions
omize
omize
ts withy superficial femoral artery.
